Drug
Levosimendan
Levosimendan: highest development phase Post-Market, developed by Orion Corporation. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Orion Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levosimendan NCT00219388 | Post-Market | Heart Failure |
| Levosimendan NCT03948178 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Levosimendan NCT03505021 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Levosimendan NCT01721434 | Phase 2/3 | Muscle Weakness Conditions |
| Levosimendan NCT01720030 | Phase 2/3 | Acute Kidney Injury |
| levosimendan NCT00130871 | Phase 2 | Coronary Heart Disease |
Latest
No recent events.
Follow Levosimendan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.